Orchestra BioMed Holdings (OBIO) Gross Profit Growth (1y) (2023 - 2026)

Orchestra BioMed Holdings (OBIO) Gross Profit Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 11.24%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 15.59%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 68.41%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 33.01%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -41.93%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 57.16%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 351.57%
10 Orchestra BioMed Holdings 265.06 Mn 80.63 Mn 63,000.00 -92.03%

Historic Data

Download Data
DateValue
Jun 30, 2026 -92.03%
Mar 31, 2026 -90.53%
Dec 31, 2025 15,728.72%
Sep 30, 2025 -11.64%
Jun 30, 2025 7.63%
Mar 31, 2025 40.61%
Dec 31, 2024 -9.30%
Sep 30, 2024 143.12%
Jun 30, 2024 -14.75%
Mar 31, 2024 -47.68%
Dec 31, 2023 -79.52%
Sep 30, 2023 -65.85%
Jun 30, 2023 152.49%
Mar 31, 2023 35.92%